JPRN-UMIN000053226尚未招募Unknown
A Retrospective Multicenter Study Regarding the Risk Factors for Lymph node Metastasis of Gastric Adenocarcinoma of Fundic Gland type - RESECT-GAFG
Graduate School of Medicine, the University of Tokyo0 个研究点目标入组 130 人开始时间: 2023年12月28日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of cancer of the stomach or other organs within 3 years of surgery. However, the following cancers, which are considered to have almost no chance of having metastasis, are not included in the exclusion criteria 1) EP/LPM cancer of the esophagus 2) M cancer of the colon 3) Differentiated M carcinoma of the stomach less than 2 cm without ulcerative changes
研究者
相似试验
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-LTBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-DEBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-CZBiogen Idec Inc160
进行中（未招募）
1 期
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12EUCTR2004-004774-85-GBBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-SEBiogen Idec Inc160